Literature DB >> 1896245

Mucosal antibodies to Haemophilus influenzae type b capsular polysaccharide.

J R Gilsdorf1, W M McDonnell.   

Abstract

Levels of salivary antibodies directed against Haemophilus influenzae b (Hib) capsule, measured by ELISA and standardized to the total salivary IgA, were compared among 57 patients with Hib infections, 117 household and 49 day care contacts of patients, and 53 control individuals with no known contact with Hib. Nineteen of the household or day care contacts were throat or nasopharyngeal culture positive for Hib. Eighty % of evaluable patients had polyribosylribitol phosphate (PRP)-specific IgA in their saliva, compared with 36% of contacts who were throat or nasopharyngeal culture positive for Hib, 53% of contacts who were throat or nasopharyngeal culture negative for Hib, and 30% of control children. In patients, no correlation between age and level of salivary anti-PRP antibody was seen, but patients less than 3 y old were more likely to have these antibodies than were older patients. Salivary PRP-specific IgA antibodies, associated with either Hib colonization or PRP vaccination, tended to decline over time. Thus, PRP-specific IgA antibodies can be identified in the saliva of children over a wide age range, including those colonized with Hib or vaccinated with PRP, but these antibodies appear to decline after antigenic stimulation ceases.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1896245     DOI: 10.1203/00006450-199105010-00002

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  3 in total

Review 1.  Mucosal immunology of vaccines against pathogenic nasopharyngeal bacteria.

Authors:  Q Zhang; A Finn
Journal:  J Clin Pathol       Date:  2004-10       Impact factor: 3.411

Review 2.  Antigenic diversity and gene polymorphisms in Haemophilus influenzae.

Authors:  J R Gilsdorf
Journal:  Infect Immun       Date:  1998-11       Impact factor: 3.441

3.  Subclass distribution of IgA antibodies in saliva and serum after immunization with Haemophilus influenzae type b conjugate vaccines.

Authors:  M Kauppi-Korkeila; L Saarinen; J Eskola; H Käyhty
Journal:  Clin Exp Immunol       Date:  1998-02       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.